Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin resubmission

Executive Summary

Genentech appears on target for a February user fee date on its resubmitted sBLA for Avastin (bevacizumab) as a first-line treatment for metastatic breast cancer in combination with paclitaxel. The firm announced the resubmission Aug. 24 and expects a six-month review. FDA requested an independent review of patient scans for progression-free survival in a "complete response" letter it sent to the firm Sept. 8 (1"The Pink Sheet" Oct. 2, 2006, p. 21). Genentech said the independent review results were consistent with its earlier positive findings...

You may also be interested in...



Genentech’s Avastin gets review panel

FDA's Oncologic Drugs Advisory Committee will review Avastin (bevacizumab) in combination with paclitaxel chemotherapy for patients who have not received chemotherapy for locally recurrent or metastatic breast cancer, Genentech announces Sept. 13. ODAC is scheduled to meet Dec. 4-5. Genentech resubmitted the sBLA in August, setting up a February 23, 2008 action date (1"The Pink Sheet" Aug. 27, 2007, In Brief). The resubmission followed a "complete response" letter issued by the agency in September 2006 that requested an independent review of patient scans for progression-free survival...

Roche Builds Off Oncology Foundation With Autoimmune, Metabolic “Pillars”

Roche views its autoimmune and metabolic disease programs as additional "therapeutic pillars" that will complement its existing strength in oncology

Happify Health Launches Prescription Digital Therapeutics To Treat Depression Or Anxiety

After raising $73m in a series D in March, Happify Health is recruiting patients in a real-world study to further evaluate its behavioral health app.

UsernamePublicRestriction

Register

PS048713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel